The latest price target for Stoke Therapeutics (NASDAQ:STOK) was reported by Chardan Capital on December 20, 2024. The analyst firm set a price target for $24.00 expecting STOK to rise to within 12 months (a possible 105.48% upside). 20 analyst firms have reported ratings in the last year.

The latest analyst rating for Stoke Therapeutics (NASDAQ:STOK) was provided by Chardan Capital, and Stoke Therapeutics initiated their buy rating.

The last upgrade for Stoke Therapeutics Inc happened on March 26, 2024 when TD Cowen raised their price target to N/A. TD Cowen previously had a hold for Stoke Therapeutics Inc.

There is no last downgrade for Stoke Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Stoke Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Stoke Therapeutics was filed on December 20, 2024 so you should expect the next rating to be made available sometime around December 20, 2025.

While ratings are subjective and will change, the latest Stoke Therapeutics (STOK) rating was a initiated with a price target of $0.00 to $24.00. The current price Stoke Therapeutics (STOK) is trading at is $11.68, which is within the analyst’s predicted range.